Schiff Nutrition president and CEO Tarang Amin promised to infuse some new energy into the company with his appointment earlier this spring, and he wasted no time with the Schiff acquisition of two probiotic brands — Sustenex and Digestive Advantage — in June.
In the year leading up to the switch of Allegra, Sanofi generated $214.2 million in U.S. prescription sales of Allegra, largely due to the generic competition against its Allegra D formulation. Now Sanofi is looking to virtually match those annual sales figures within the much more profitable nonprescription venue with the company’s successful switch from prescription to OTC this spring.
Energy shots have delivered a jolt to pharmacy sales to the tune of an incremental $50 million in the past year. That business was borne out of targeting the typical all-nighters: college kids cramming for exams, truck drivers and third-shift workers. But seniors?